ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine

Ulker M., Duman B. B., ŞAHİN B., GÜMÜRDÜLÜ D.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.19, no.3, pp.207-213, 2015 (ESCI) identifier identifier identifier


Background: We aimed to investigate the impact of RRM1 and ERCC1 expression on response to cisplatin and/or gemcitabine chemotherapy in patients with lung, ovarian or pancreatic cancer.